Peritransplant Soluble CD30 as a Risk Factor for Slow Kidney Allograft Function, Early Acute Rejection, Worse Long-Term Allograft Function, and Patients’ Survival
Table 4
Median sCD30 levels according to initial graft function and presence of acute rejection and early pyelonephritis.
Groups of patients
n
Pretransplant sCD30
Posttransplant sCD30
value
Initial graft function
IGF
20
51.3 (34.5–70.6)
21.3 (14.6–41.3)
SGF
5
27.3 (21.7–36.9)
19.9 (11.7–23.1)
DGF
8
53.5 (39.7–72.9)
32.8 (25.7–39.9)
Acute rejection
Without AR
23
46.6 (30.8–70.6)
26.6 (12.4–40.1)
AR at any time
11
47.1 (36.9–60.2)
21.3 (15.7–34.0)
Very early AR (0–7th day)
5
56.1 (51.0–60.2)
21.2 (15.7–55.2)
Early AR (the 8th day–6 months)
3
60.2 (43.3–70.7)
23.5 (21.4–56.7)
Late AR (>6 months)
3
36.9 (17.1–40.9)
16.1 (9.2–34.0)
Early pyelonephritis (the 8th day–2 months)
No
29
49.5 (36.9–64.2)
26.6 (15.8–40.1)
Yes
4
24.5 (16.7–49.0)
16.5 (11.2–22.2)
sCD30: soluble CD30; IGF: immediate graft function; SGF: slow graft function; DGF: delayed graft function; AR: acute rejection; n: number of patients investigated. Median (interquartile range).